首页> 美国卫生研究院文献>Annals of the Rheumatic Diseases >Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound NRD101 in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis
【2h】

Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound NRD101 in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis

机译:在一项为期一年的有症状膝骨关节炎的随机对照研究中评估了一种新的透明质酸化合物NRD101与双醋瑞因和安慰剂的对症和结构功效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Objective: To evaluate long term efficacy of three iterative courses of three weekly intra-articular (IA) injections of NRD101 in the treatment of symptomatic knee osteoarthritis (OA). >Patients and methods: A 1 year prospective, multicentre, randomised, double blind, placebo controlled study of 301 patients aged >50 years with painful and radiological medial knee OA. Patients were randomly assigned into three groups receiving: (1) three courses of three IA injections of hyaluronic acid (HA) + oral placebo; (2) IA injections of saline solution + diacerein 100 mg/day; (3) IA injections of saline solution + oral placebo. Demographic data and symptomatic criteria—pain, Lequesne's index, patient's global assessment of disease activity, percentage of painful days—were obtained during the study; primary structural criterion was JSW. Efficacy criteria were changes in pain VAS, joint space narrowing (JSN), and percentage of progressors (JSN >0.5 mm). An intention to treat analysis was used for symptomatic variables, and completer analysis for structural variables. >Results: Baseline characteristics were similar between the three groups. Mean (SD) improvement in pain VAS was clinically relevant (–33.9 (27.3), n = 301), but with no difference between the groups (p = 0.96). JSW deteriorated (–0.09 (0.55) mm, n = 277, p = 0.01), but with no difference between the groups (p = 0.82). Percentages of progressors were 17.7, 18.9, and 20.3% (p = 0.90), in groups 1, 2, and 3, respectively. >Conclusion: A weak but statistically significant structural deterioration occurred over 1 year, together with clinically relevant symptomatic improvement in patients receiving oral drug and iterative IA injections. Symptomatic and/or structural effects for both this new HA compound and diacerein were not demonstrated.
机译:>目的:评估每周3次NRD101关节内(IA)注射的三个迭代疗程对有症状的膝骨关节炎(OA)的长期疗效。 >患者和方法:这项为期1年,前瞻性,多中心,随机,双盲,安慰剂对照的研究对301例> 50岁的疼痛和放射性内侧膝OA的患者进行了研究。将患者随机分为三组,分别为:(1)IA透明质酸(HA)+口服安慰剂3次IA注射3个疗程; (2)IA注射盐溶液+双醋瑞因100 mg /天; (3)IA注射盐溶液+口服安慰剂。在研究过程中获得了人口统计学数据和症状标准(疼痛,Lequesne指数,患者对疾病活动的整体评估,痛苦天数的百分比);主要的结构标准是JSW。疗效标准为疼痛VAS,关节间隙变窄(JSN)和进展百分比(JSN> 0.5 mm)的变化。对症状变量使用治疗分析的意图,对结构变量使用更完整的分析。 >结果:三组之间的基线特征相似。疼痛VAS的平均改善(SD)与临床相关(–33.9(27.3),n = 301),但两组之间无差异(p = 0.96)。 JSW恶化(–0.09(0.55)mm,n = 277,p = 0.01),但两组之间无差异(p = 0.82)。第1、2和3组中进步者的百分比分别为17.7%,18.9%和20.3%(p = 0.90)。 >结论:接受口服药物和IA反复注射的患者在1年中出现了结构较弱但有统计学意义的结构恶化,同时临床症状也有所改善。没有显示这种新的HA化合物和双醋瑞因的症状和/或结构效果。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号